Merck & (MRK) Stock

$88.20 0.15 (0.17%)
Market Cap: $223.11B | NYSE

Merck & Chart


Company Profile

Price: $88.20

Market Cap: $223.11B

Exchange: NYSE

CEO: Mr. Robert M. Davis J.D.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 70.00K

Headquarters: Kenilworth, NJ

Website: Merck &

Business Summary

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & News

Merck & Co., Inc. (MRK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

News image

Investors who lost money on Merck & Co., Inc. should contact Levi & Korsinsky about an ongoing investigation - MRK

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

News image

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

News image

Merck: Don't Fight The Tape, How Low Can It Go?

Despite Merck & Co., Inc.'s strong fundamentals and promising pipeline, current negative sentiment suggests avoiding the stock until it stabilizes and shows signs of recovery. Merck's stock is undervalued but could face further declines, with potential prices dropping to $80, $70, or even $60. The stock market's irrationality can outlast your solvency; avoid the pain of catching a falling knife by waiting for a confirmed bottom in MRK stock.

News image

Why Merck (MRK) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

News image

Should You Pick MRK Stock At $90?

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates of $15.5 billion and $1.62, respectively.

News image

Final Trade: SNAP, PYPL, SPYV, MRK

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

News image

Merck & Co., Inc. (MRK) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

News image

Guggenheim Securities' Vamil Divan breaks down Merck's stock drop

Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.

News image

Merck: Ideal Case Of Why I Love Option Collars (Upgrade To Buy)

Merck's current high-risk profile led me to initially rate it a strong sell, but recent technical indicators suggested a potential bottom near $100. I've upgraded MRK to a buy, using a "Dog Collar" strategy: buying a put option and selling a call option to limit risk. This approach offers controlled outcomes, with $18 upside and $7 downside risk, ensuring I manage risk while seeking potential gains.

News image

Why Merck Stock Is Plummeting Today

Shares of Merck (MRK -9.66%) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m.

News image

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Healthcare costs are rising, with PwC projecting the highest commercial healthcare spending growth in 13 years, impacting consumers and insurance companies negatively. Healthcare stocks, including Merck & Co., Inc., have underperformed the S&P 500, making them attractive as the broader market reaches high valuations. Despite Merck's recent 30% stock decline due to poor guidance and Gardasil challenges, I believe it offers good long-term value.

News image

Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK ) Q4 2024 Results Conference Call February 4, 2025 9:00 AM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dr. Dean Li - President of Merck Research Labs Conference Call Participants Umer Raffat - Evercore ISI Terence Flynn - Morgan Stanley Luisa Hector - Berenberg Mohit Bansal - Wells Fargo Daina Graybosch - Leerink Partners Geoff Meacham - Citi Chris Schott - JPMorgan Tim Anderson - Bank of America Akash Tewari - Jefferies Trung Huynh - UBS Vamil Divan - Guggenheim Courtney Breen - Bernstein James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Company Q4 Sales and Earnings Conference Call.

News image

Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.

News image

Merck shares plunge on weak 2025 outlook, pause in Gardasil shipments to China

Merck & Co Inc (NYSE:MRK, ETR:6MK) shares fell more than 10% after the drugmaker issued weak guidance for 2025 and announced it would halt shipments of its HPV vaccine Gardasil to China until at least the middle of the year due to declining demand. It reported a 17% year-over-year decline in Gardasil sales to $1.55 billion for the fourth quarter.

News image

Merck (MRK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News image

Merck Stock Slumps as Q4 Profits, 2025 Forecast Fall Short

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue that topped expectations.

News image

2 Blue-Chip Drug Stocks in Focus Today After Earnings

Stocks are struggling for direction  today, and one sector that represents this choppiness is blue-chip drugmakers.

News image

Merck (MRK) Tops Q4 Earnings and Revenue Estimates

Merck (MRK) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $0.03 per share a year ago.

News image

Mizuho's Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocks

Jared Holz, Mizuho Securities America healthcare sector strategist, joins 'Squawk Box' to break down the quarterly earnings results of Merck and Pfizer, 2025 outlook for pharmaceutical stocks, and more.

News image

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook

On Tuesday, Merck & Co Inc MRK reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%.

News image

Merck's soft guidance overshadows quarterly beat to send stock down 6%

Merck's stock tumbled 6% early Tuesday, after the drug company's softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

News image

Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China

Merck on issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February through and going through at least mid-2025.

News image

Merck pauses Gardasil shipments to China, hitting its 2025 outlook

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.

News image

Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results.

News image

The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals

The Dow Jones industrial average (DJIA) is a price-weighted average of 30 blue-chip U.S.

News image

Gardasil Worries Loom as Merck Reports Earnings

Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China

News image

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?

Merck & Co Inc MRK and Pfizer Inc PFE are duking it out for investor attention with fourth-quarter earnings being reported on Tuesday.

News image

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.

News image

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.

News image

Merck & Earnings

This section highlights Merck & 's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 24, 2025
Time: Before Market
Est. EPS: $2.15
Status: Unconfirmed

Last Earnings Results

Date: February 04, 2025
EPS: $1.72
Est. EPS: $1.85
Revenue: $15.62B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-04 $1.85 $1.72
Read Transcript Q3 2024 2024-10-31 $1.50 $1.57
Read Transcript Q2 2024 2024-07-30 $2.15 $2.28
Read Transcript Q1 2024 2024-04-25 $1.88 $2.07
Read Transcript Q4 2023 2024-02-01 $-0.09 $0.03
Read Transcript Q3 2023 2023-10-26 $1.95 $2.13
Read Transcript Q2 2023 2023-08-01 $-2.17 $-2.06
Read Transcript Q1 2023 2023-04-27 $1.32 $1.40

Financial Statements

Access annual & quarterly financial statements for Merck & , including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $60.12B $59.28B $48.70B $41.52B $46.84B
Cost of Revenue $16.13B $17.41B $13.63B $13.62B $14.11B
Gross Profit $43.99B $41.87B $35.08B $27.90B $32.73B
Gross Profit Ratio 73.17% 70.63% 72.02% 67.20% 69.87%
Research and Development Expenses $30.53B $13.55B $12.24B $13.40B $9.87B
General and Administrative Expenses $8.20B $7.84B $7.63B $7.16B $8.71B
Selling and Marketing Expenses $2.30B $2.20B $2.00B $1.80B $1.90B
Selling General and Administrative Expenses $10.50B $10.04B $9.63B $8.96B $10.62B
Other Expenses $- $960.00M $468.00M $469.00M $-139.00M
Operating Expenses $40.91B $23.59B $21.88B $22.35B $20.49B
Cost and Expenses $57.16B $41.00B $35.51B $35.97B $34.60B
Interest Income $365.00M $157.00M $36.00M $59.00M $274.00M
Interest Expense $1.15B $962.00M $806.00M $831.00M $893.00M
Depreciation and Amortization $3.87B $3.91B $3.21B $3.49B $3.65B
EBITDA $6.91B $21.32B $17.90B $10.18B $16.01B
EBITDA Ratio 11.49% 39.32% 34.73% 23.03% 27.50%
Operating Income $2.95B $19.40B $13.70B $6.08B $9.23B
Operating Income Ratio 4.91% 32.72% 28.14% 14.63% 19.70%
Total Other Income Expenses Net $-1.06B $-1.84B $680.00M $315.00M $3.54B
Income Before Tax $1.89B $16.44B $13.88B $8.79B $11.46B
Income Before Tax Ratio 3.14% 27.74% 28.50% 21.17% 24.47%
Income Tax Expense $1.51B $1.92B $1.52B $1.71B $1.69B
Net Income $365.00M $14.52B $13.05B $7.07B $9.84B
Net Income Ratio 0.61% 24.49% 26.79% 17.02% 21.01%
EPS $0.14 $5.73 $5.16 $2.79 $3.84
EPS Diluted $0.14 $5.71 $5.14 $2.78 $3.82
Weighted Average Shares Outstanding 2.61B 2.53B 2.53B 2.53B 2.56B
Weighted Average Shares Outstanding Diluted 2.55B 2.54B 2.54B 2.54B 2.58B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $16.66B $16.16B $15.78B $14.63B $15.96B $15.04B $14.49B $13.83B $14.96B $14.59B $15.90B $13.52B $13.15B $11.40B $10.63B $12.52B $10.93B $9.35B $12.06B $11.87B
Cost of Revenue $4.08B $4.29B $3.54B $3.91B $4.26B $4.02B $3.93B $3.88B $3.93B $4.22B $5.38B $3.87B $3.45B $3.10B $3.20B $5.53B $3.01B $2.75B $3.31B $3.67B
Gross Profit $12.58B $11.86B $12.23B $10.72B $11.70B $11.01B $10.56B $9.95B $11.03B $10.38B $10.52B $9.65B $9.70B $8.30B $7.43B $6.98B $7.92B $6.61B $8.74B $8.20B
Gross Profit Ratio 75.51% 73.43% 77.56% 73.26% 73.29% 73.24% 72.90% 71.94% 73.70% 71.11% 66.17% 71.35% 73.77% 72.78% 69.90% 55.79% 72.43% 70.63% 72.53% 69.08%
Research and Development Expenses $5.86B $2.89B $3.99B $9.63B $3.31B $13.32B $4.28B $3.77B $4.40B $2.80B $2.58B $3.07B $2.44B $4.32B $2.41B $5.84B $3.35B $2.08B $2.21B $2.55B
General and Administrative Expenses $- $- $- $504.00M $- $- $- $487.00M $- $- $- $830.00M $- $- $- $1.28B $- $- $- $789.00M
Selling and Marketing Expenses $- $- $- $2.30B $- $- $- $2.20B $- $- $- $2.00B $- $- $- $1.80B $- $- $- $2.10B
Selling General and Administrative Expenses $2.73B $2.71B $2.48B $2.80B $2.52B $2.70B $2.48B $2.69B $2.52B $2.51B $2.32B $2.83B $2.34B $2.28B $2.19B $3.08B $2.06B $2.08B $2.56B $2.89B
Other Expenses $- $203.00M $203.00M $224.00M $236.00M $233.00M $-348.00M $290.00M $242.00M $157.00M $275.00M $224.00M $2.00M $130.00M $111.00M $134.00M $156.00M $55.00M $118.00M $294.00M
Operating Expenses $8.49B $5.59B $6.47B $12.43B $5.83B $16.02B $6.75B $6.46B $6.92B $5.31B $4.90B $5.90B $4.78B $6.60B $4.60B $8.92B $5.41B $4.17B $4.76B $5.44B
Cost and Expenses $12.67B $9.89B $10.02B $16.34B $10.09B $20.05B $10.68B $10.34B $10.85B $9.53B $10.28B $9.77B $8.23B $9.71B $7.80B $14.46B $8.42B $6.92B $8.08B $9.11B
Interest Income $127.00M $69.00M $73.00M $70.00M $73.00M $109.00M $112.00M $95.00M $40.00M $15.00M $7.00M $9.00M $7.00M $9.00M $11.00M $11.00M $9.00M $14.00M $25.00M $49.00M
Interest Expense $330.00M $310.00M $303.00M $310.00M $317.00M $277.00M $242.00M $235.00M $244.00M $240.00M $243.00M $209.00M $196.00M $202.00M $200.00M $207.00M $203.00M $209.00M $212.00M $219.00M
Depreciation and Amortization $1.19B $1.06B $984.00M $964.00M $1.01B $903.00M $991.00M $892.00M $959.00M $938.00M $1.12B $835.00M $759.00M $728.00M $892.00M $904.00M $807.00M $975.00M $821.00M $936.00M
EBITDA $5.61B $7.38B $6.96B $-772.00M $7.20B $-4.16B $4.88B $4.64B $4.79B $5.67B $6.22B $4.95B $6.22B $2.61B $3.84B $-881.00M $3.72B $3.48B $4.87B $3.95B
EBITDA Ratio 33.66% 45.39% 44.50% -3.11% 45.08% -25.05% 31.48% 34.45% 35.74% 42.33% 44.17% 35.63% 43.26% 22.48% 36.16% -7.12% 31.83% 37.21% 41.01% 34.05%
Operating Income $3.98B $6.27B $6.04B $-1.42B $6.18B $-4.67B $3.57B $3.87B $4.39B $5.24B $5.90B $3.98B $4.93B $1.83B $2.95B $-1.79B $2.67B $2.50B $4.12B $3.10B
Operating Income Ratio 23.92% 38.80% 38.26% -9.70% 38.72% -31.06% 24.64% 28.00% 29.33% 35.90% 37.13% 29.45% 37.49% 16.09% 27.77% -14.34% 24.45% 26.78% 34.20% 26.16%
Total Other Income Expenses Net $106.00M $-263.00M $-90.00M $-627.00M $-252.00M $-323.00M $-156.00M $26.00M $-523.00M $-580.00M $-761.00M $160.00M $343.00M $21.00M $150.00M $-198.00M $198.00M $307.00M $-143.00M $-313.00M
Income Before Tax $4.09B $6.01B $5.67B $-2.05B $5.62B $-5.33B $3.65B $3.51B $3.58B $4.49B $4.86B $3.91B $5.27B $1.72B $3.46B $-1.99B $3.43B $3.52B $3.84B $2.79B
Income Before Tax Ratio 24.55% 37.18% 35.94% -13.98% 35.21% -35.48% 25.20% 25.40% 23.95% 30.75% 30.57% 28.91% 40.03% 15.06% 32.58% -15.92% 31.37% 37.62% 31.83% 23.53%
Income Tax Expense $929.00M $545.00M $903.00M $-821.00M $870.00M $637.00M $825.00M $495.00M $330.00M $538.00M $554.00M $85.00M $695.00M $503.00M $276.00M $99.00M $483.00M $509.00M $619.00M $428.00M
Net Income $3.16B $5.46B $4.76B $-1.23B $4.75B $-5.97B $2.82B $3.02B $3.25B $3.94B $4.31B $3.76B $4.57B $1.54B $3.18B $-2.09B $2.94B $3.00B $3.22B $2.36B
Net Income Ratio 18.95% 33.76% 30.19% -8.38% 29.73% -39.74% 19.47% 21.81% 21.71% 27.03% 27.11% 27.79% 34.72% 13.55% 29.91% -16.73% 26.91% 32.10% 26.70% 19.85%
EPS $1.25 $2.15 $1.88 $-0.48 $1.87 $-2.35 $1.11 $1.19 $1.28 $1.56 $1.70 $1.49 $1.81 $0.61 $1.26 $-0.83 $1.16 $1.19 $1.28 $0.93
EPS Diluted $1.24 $2.14 $1.87 $-0.48 $1.86 $-2.35 $1.11 $1.18 $1.28 $1.55 $1.70 $1.48 $1.80 $0.61 $1.25 $-0.82 $1.16 $1.18 $1.26 $0.92
Weighted Average Shares Outstanding 2.53B 2.53B 2.53B 2.55B 2.54B 2.54B 2.54B 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.52B 2.54B
Weighted Average Shares Outstanding Diluted 2.54B 2.54B 2.54B 2.55B 2.55B 2.54B 2.55B 2.55B 2.54B 2.54B 2.54B 2.54B 2.54B 2.54B 2.54B 2.54B 2.54B 2.54B 2.55B 2.56B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $6.84B $12.69B $8.10B $8.06B $9.68B
Short Term Investments $252.00M $498.00M $- $1.00M $774.00M
Cash and Short Term Investments $7.09B $13.19B $8.10B $8.06B $10.45B
Net Receivables $10.35B $9.45B $9.23B $7.24B $6.78B
Inventory $6.36B $5.91B $5.95B $6.31B $5.98B
Other Current Assets $8.37B $7.17B $6.99B $6.92B $4.28B
Total Current Assets $32.17B $35.72B $30.27B $27.76B $27.48B
Property Plant Equipment Net $24.49B $21.42B $19.28B $17.99B $15.05B
Goodwill $21.20B $21.20B $21.26B $20.24B $19.43B
Intangible Assets $18.01B $20.27B $22.93B $14.60B $14.20B
Goodwill and Intangible Assets $39.21B $41.47B $44.20B $34.84B $33.62B
Long Term Investments $252.00M $1.01B $370.00M $785.00M $1.47B
Tax Assets $1.31B $1.79B $3.44B $1.01B $1.47B
Other Non-Current Assets $10.56B $7.73B $8.14B $9.20B $5.30B
Total Non-Current Assets $74.51B $73.44B $75.43B $63.82B $56.91B
Other Assets $- $- $- $- $-
Total Assets $106.67B $109.16B $105.69B $91.59B $84.40B
Account Payables $3.92B $4.26B $4.61B $4.33B $3.74B
Short Term Debt $1.66B $1.95B $2.41B $6.72B $3.61B
Tax Payables $2.65B $1.99B $1.22B $1.57B $736.00M
Deferred Revenue $- $- $- $- $-
Other Current Liabilities $17.47B $16.04B $15.63B $14.70B $14.14B
Total Current Liabilities $25.69B $24.24B $23.87B $27.33B $22.22B
Long Term Debt $34.61B $29.76B $31.91B $26.70B $23.50B
Deferred Revenue Non-Current $- $- $- $- $-
Deferred Tax Liabilities Non-Current $871.00M $1.79B $3.44B $1.01B $1.47B
Other Non-Current Liabilities $7.86B $7.31B $8.21B $11.16B $11.20B
Total Non-Current Liabilities $43.35B $38.86B $43.56B $38.86B $36.18B
Other Liabilities $- $- $- $- $-
Total Liabilities $69.04B $63.10B $67.44B $66.18B $58.40B
Preferred Stock $- $- $- $- $-
Common Stock $1.79B $1.79B $1.79B $1.79B $1.79B
Retained Earnings $53.90B $61.08B $53.70B $47.36B $46.60B
Accumulated Other Comprehensive Income Loss $-5.16B $-4.77B $-4.43B $-6.63B $-6.19B
Other Total Stockholders Equity $-12.94B $-12.11B $-12.87B $-17.20B $-16.29B
Total Stockholders Equity $37.58B $45.99B $38.18B $25.32B $25.91B
Total Equity $37.63B $46.06B $38.26B $25.40B $26.00B
Total Liabilities and Stockholders Equity $106.67B $109.16B $105.69B $91.59B $84.40B
Minority Interest $54.00M $67.00M $73.00M $87.00M $94.00M
Total Liabilities and Total Equity $106.67B $109.16B $105.69B $91.59B $84.40B
Total Investments $1.84B $1.51B $370.00M $785.00M $2.24B
Total Debt $36.27B $30.69B $33.10B $31.79B $26.35B
Net Debt $29.43B $18.00B $25.01B $23.73B $16.67B


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $14.59B $11.35B $5.67B $6.91B $8.64B $5.70B $9.74B $12.69B $11.14B $9.68B $8.56B $8.10B $10.02B $8.57B $6.98B $8.06B $7.36B $11.10B $7.42B $9.68B
Short Term Investments $- $50.00M $40.00M $252.00M $168.00M $718.00M $680.00M $498.00M $103.00M $453.00M $372.00M $- $26.00M $12.00M $16.00M $785.00M $6.00M $10.00M $7.00M $774.00M
Cash and Short Term Investments $14.59B $11.40B $5.71B $7.16B $8.81B $6.42B $10.42B $13.19B $11.25B $10.13B $8.93B $8.10B $10.02B $8.57B $6.98B $8.06B $7.36B $11.10B $7.43B $10.45B
Net Receivables $11.38B $11.64B $12.57B $11.70B $11.67B $12.29B $11.58B $9.45B $9.48B $9.64B $9.83B $9.23B $8.57B $7.84B $8.23B $7.85B $8.42B $7.58B $8.18B $6.78B
Inventory $6.24B $6.47B $6.51B $6.36B $6.13B $5.93B $5.86B $5.91B $5.61B $5.54B $5.77B $5.95B $7.98B $7.91B $8.58B $6.31B $8.21B $7.98B $7.48B $5.98B
Other Current Assets $8.14B $8.74B $6.74B $7.01B $5.38B $5.38B $5.58B $7.17B $7.22B $6.81B $6.65B $6.99B $6.87B $6.75B $5.29B $5.54B $4.67B $4.61B $4.71B $4.28B
Total Current Assets $40.36B $38.20B $31.45B $32.17B $31.95B $29.98B $33.40B $35.72B $33.56B $32.12B $31.18B $30.27B $31.06B $28.66B $26.91B $27.76B $26.58B $29.34B $26.17B $27.48B
Property Plant Equipment Net $23.45B $23.22B $23.05B $24.49B $22.53B $22.23B $21.76B $21.42B $20.42B $20.06B $19.75B $19.28B $18.57B $18.06B $18.30B $17.99B $16.92B $15.79B $15.27B $15.05B
Goodwill $21.70B $21.16B $21.18B $21.20B $21.18B $21.20B $21.21B $21.20B $21.16B $21.21B $21.26B $21.26B $18.86B $18.87B $20.21B $20.24B $20.25B $20.07B $19.77B $19.43B
Intangible Assets $17.01B $16.98B $17.57B $18.01B $19.20B $19.66B $19.86B $20.27B $21.37B $22.50B $23.02B $22.93B $13.38B $13.62B $14.40B $14.60B $16.68B $16.57B $16.10B $14.20B
Goodwill and Intangible Assets $38.71B $38.15B $38.75B $39.21B $40.38B $40.86B $41.07B $41.47B $42.53B $43.71B $44.28B $44.20B $32.25B $32.49B $34.61B $34.84B $36.92B $36.63B $35.86B $33.62B
Long Term Investments $575.00M $1.65B $1.59B $1.58B $2.69B $2.83B $2.99B $1.01B $984.00M $238.00M $316.00M $370.00M $435.00M $411.00M $544.00M $785.00M $1.37B $1.25B $555.00M $1.47B
Tax Assets $- $876.00M $922.00M $- $1.02B $996.00M $- $1.79B $2.42B $2.97B $3.07B $3.44B $1.53B $1.49B $1.20B $1.01B $1.78B $2.09B $1.94B $1.47B
Other Non-Current Assets $864.00M $10.53B $10.10B $9.23B $8.16B $7.58B $8.58B $7.73B $7.17B $8.00B $8.07B $8.14B $9.66B $9.56B $9.28B $9.20B $6.23B $5.51B $5.11B $5.30B
Total Non-Current Assets $63.59B $74.42B $74.40B $74.51B $74.77B $74.49B $74.39B $73.44B $73.52B $74.98B $75.48B $75.43B $62.44B $62.02B $63.94B $63.82B $63.22B $61.27B $58.74B $56.91B
Other Assets $13.58B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $117.53B $112.63B $105.85B $106.67B $106.73B $104.47B $107.80B $109.16B $107.08B $107.09B $106.67B $105.69B $93.49B $90.69B $90.85B $91.59B $89.80B $90.61B $84.91B $84.40B
Account Payables $3.59B $3.52B $3.51B $3.92B $3.51B $3.44B $3.68B $4.26B $3.37B $3.48B $3.71B $4.61B $3.37B $3.90B $4.03B $4.59B $3.74B $3.45B $3.57B $3.74B
Short Term Debt $3.15B $3.07B $3.08B $1.66B $887.00M $2.84B $2.67B $1.95B $1.94B $2.98B $1.21B $2.41B $3.53B $2.49B $7.25B $6.72B $2.42B $4.72B $6.36B $3.61B
Tax Payables $4.33B $2.78B $2.40B $2.65B $1.98B $1.49B $1.87B $1.99B $1.70B $1.44B $1.57B $1.22B $954.00M $971.00M $1.49B $1.57B $984.00M $1.27B $1.03B $736.00M
Deferred Revenue $- $2.78B $2.40B $4.63B $3.86B $3.37B $3.78B $- $2.42B $2.97B $- $- $954.00M $971.00M $1.49B $1.01B $- $- $- $-
Other Current Liabilities $18.52B $16.69B $16.11B $17.47B $16.72B $15.62B $14.91B $16.04B $15.99B $15.27B $15.82B $15.63B $15.87B $14.55B $13.59B $14.44B $13.26B $12.75B $12.52B $14.14B
Total Current Liabilities $29.59B $26.06B $25.10B $25.69B $23.09B $23.39B $23.13B $24.24B $23.00B $23.17B $22.32B $23.87B $23.73B $21.91B $26.36B $27.33B $20.41B $22.18B $23.48B $22.22B
Long Term Debt $34.98B $34.72B $31.14B $34.61B $33.97B $34.07B $28.07B $29.76B $28.48B $28.68B $30.59B $31.91B $22.91B $24.03B $24.00B $26.72B $26.32B $26.16B $21.64B $23.50B
Deferred Revenue Non-Current $- $- $- $928.00M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $876.00M $922.00M $871.00M $1.02B $996.00M $1.44B $1.79B $2.42B $2.97B $3.07B $3.44B $1.53B $1.49B $1.20B $1.01B $1.78B $2.09B $1.94B $1.47B
Other Non-Current Liabilities $- $7.33B $8.26B $7.86B $7.34B $7.26B $8.24B $7.31B $8.66B $8.95B $9.74B $8.21B $9.47B $9.87B $12.24B $11.12B $12.03B $12.45B $11.55B $11.20B
Total Non-Current Liabilities $34.98B $42.92B $40.33B $43.35B $42.33B $42.33B $37.76B $38.86B $39.56B $40.61B $43.40B $43.56B $33.90B $35.39B $37.45B $38.86B $40.12B $40.69B $35.13B $36.18B
Other Liabilities $8.40B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $72.97B $68.98B $65.42B $69.04B $65.43B $65.73B $60.89B $63.10B $62.56B $63.78B $65.72B $67.44B $57.63B $57.30B $63.81B $66.18B $60.53B $62.87B $58.61B $58.40B
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B $1.79B
Retained Earnings $61.38B $60.19B $56.70B $53.90B $57.08B $54.20B $62.04B $61.08B $59.93B $58.44B $56.25B $53.70B $51.69B $48.78B $48.89B $47.36B $51.11B $49.72B $48.27B $46.60B
Accumulated Other Comprehensive Income Loss $-5.37B $-5.36B $-5.27B $-5.16B $-4.92B $-4.90B $-4.88B $-4.77B $-4.74B $-4.33B $-4.37B $-4.43B $-4.59B $-4.63B $-6.62B $-6.63B $-6.38B $-6.39B $-6.39B $-6.19B
Other Total Stockholders Equity $-13.30B $-13.03B $-12.85B $-12.94B $-12.71B $-12.39B $-12.11B $-12.11B $-12.52B $-12.65B $-12.79B $-12.87B $-13.10B $-12.64B $-17.11B $-17.20B $-17.33B $-17.48B $-17.46B $-16.29B
Total Stockholders Equity $44.50B $43.58B $40.36B $37.58B $41.25B $38.69B $46.83B $45.99B $44.46B $43.24B $40.88B $38.18B $35.79B $33.29B $26.95B $25.32B $29.19B $27.64B $26.20B $25.91B
Total Equity $44.56B $43.65B $40.42B $37.63B $41.30B $38.74B $46.91B $46.06B $44.52B $43.32B $40.95B $38.26B $35.86B $33.39B $27.04B $25.40B $29.27B $27.74B $26.30B $26.00B
Total Liabilities and Stockholders Equity $117.53B $112.63B $105.85B $106.67B $106.73B $104.47B $107.80B $109.16B $107.08B $107.09B $106.67B $105.69B $93.49B $90.69B $90.85B $91.59B $89.80B $90.61B $84.91B $84.40B
Minority Interest $58.00M $66.00M $60.00M $54.00M $54.00M $49.00M $71.00M $67.00M $66.00M $75.00M $70.00M $73.00M $69.00M $94.00M $94.00M $87.00M $84.00M $102.00M $95.00M $94.00M
Total Liabilities and Total Equity $117.53B $112.63B $105.85B $106.67B $106.73B $104.47B $107.80B $109.16B $107.08B $107.09B $106.67B $105.69B $93.49B $90.69B $90.85B $91.59B $89.80B $90.61B $84.91B $84.40B
Total Investments $575.00M $1.70B $1.63B $1.84B $2.85B $3.55B $3.67B $1.51B $1.09B $691.00M $688.00M $370.00M $435.00M $411.00M $544.00M $1.57B $1.37B $1.25B $562.00M $2.24B
Total Debt $38.13B $37.79B $34.22B $36.27B $34.86B $36.91B $30.75B $30.69B $30.42B $31.66B $31.79B $33.10B $26.44B $26.52B $31.25B $31.79B $28.74B $30.87B $28.00B $26.35B
Net Debt $23.54B $26.44B $28.55B $29.36B $26.21B $31.21B $21.01B $18.00B $19.27B $21.99B $23.24B $25.01B $16.43B $17.95B $24.27B $23.73B $21.39B $19.77B $20.57B $16.67B

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $365.00M $14.53B $12.36B $7.08B $9.78B
Depreciation and Amortization $3.87B $3.91B $3.21B $3.62B $3.65B
Deferred Income Tax $-1.90B $-1.57B $187.00M $-668.00M $-556.00M
Stock Based Compensation $645.00M $541.00M $479.00M $441.00M $417.00M
Change in Working Capital $-2.21B $-2.78B $-3.84B $-4.59B $-2.07B
Accounts Receivables $-1.15B $-644.00M $-2.03B $-1.00B $294.00M
Inventory $-816.00M $-161.00M $-674.00M $-855.00M $-508.00M
Accounts Payables $-380.00M $-289.00M $405.00M $724.00M $399.00M
Other Working Capital $139.00M $-1.69B $-1.54B $-3.46B $-2.25B
Other Non Cash Items $12.23B $4.47B $1.71B $4.33B $2.22B
Net Cash Provided by Operating Activities $13.01B $19.09B $14.11B $10.25B $13.44B
Investments in Property Plant and Equipment $-3.86B $-4.39B $-4.45B $-4.68B $-3.47B
Acquisitions Net $-12.03B $-121.00M $-12.91B $-6.61B $-4.95B
Purchases of Investments $-955.00M $-1.20B $-1.00M $-1.09B $-3.20B
Sales Maturities of Investments $1.66B $721.00M $1.03B $2.81B $8.62B
Other Investing Activities $1.11B $32.00M $-225.00M $130.00M $378.00M
Net Cash Used for Investing Activities $-14.08B $-4.96B $-16.55B $-9.44B $-2.63B
Debt Repayment $4.18B $-2.25B $1.63B $5.01B $1.25B
Common Stock Issued $- $384.00M $- $- $-
Common Stock Repurchased $-1.35B $-384.00M $-840.00M $-1.28B $-4.78B
Dividends Paid $-7.45B $-7.01B $-6.61B $-6.21B $-5.70B
Other Financing Activities $-203.00M $144.00M $8.41B $-347.00M $366.00M
Net Cash Used Provided by Financing Activities $-4.81B $-9.12B $2.59B $-2.83B $-8.86B
Effect of Forex Changes on Cash $23.00M $-410.00M $-133.00M $253.00M $17.00M
Net Change in Cash $-5.86B $4.61B $14.00M $-1.77B $1.97B
Cash at End of Period $6.91B $12.77B $8.17B $8.16B $9.93B
Cash at Beginning of Period $12.77B $8.17B $8.15B $9.93B $7.97B
Operating Cash Flow $13.01B $19.09B $14.11B $10.25B $13.44B
Capital Expenditure $-3.86B $-4.39B $-4.45B $-4.68B $-3.47B
Free Cash Flow $9.14B $14.71B $9.66B $5.57B $9.97B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $3.16B $5.46B $4.76B $-1.23B $4.75B $-5.97B $2.82B $3.02B $3.25B $3.95B $4.31B $3.82B $4.57B $777.00M $3.19B $-2.09B $2.94B $3.01B $3.22B $2.36B
Depreciation and Amortization $1.19B $1.06B $984.00M $964.00M $1.01B $903.00M $991.00M $892.00M $959.00M $938.00M $1.12B $835.00M $759.00M $690.00M $930.00M $904.00M $852.00M $1.05B $821.00M $936.00M
Deferred Income Tax $-401.00M $-181.00M $-51.00M $-931.00M $-336.00M $-355.00M $-277.00M $-307.00M $-661.00M $-262.00M $-338.00M $159.00M $-1.00M $39.00M $-10.00M $-715.00M $-75.00M $40.00M $82.00M $-170.00M
Stock Based Compensation $195.00M $203.00M $176.00M $167.00M $164.00M $169.00M $145.00M $145.00M $139.00M $137.00M $120.00M $119.00M $117.00M $132.00M $111.00M $121.00M $116.00M $105.00M $108.00M $111.00M
Change in Working Capital $2.58B $-1.01B $-3.38B $144.00M $2.18B $-1.64B $-2.89B $-347.00M $263.00M $-1.40B $-1.30B $-45.00M $-139.00M $-1.55B $-2.10B $1.05B $-1.45B $-527.00M $-3.67B $1.40B
Accounts Receivables $- $- $- $-1.15B $- $- $- $-644.00M $- $- $- $-2.03B $- $- $- $-1.00B $- $- $- $294.00M
Inventory $- $- $- $-816.00M $- $- $- $-161.00M $- $- $- $-674.00M $- $- $- $-895.00M $- $- $- $-508.00M
Accounts Payables $- $- $- $- $- $- $- $41.00M $- $- $- $- $- $- $- $- $- $- $- $-
Other Working Capital $2.58B $-1.01B $-3.38B $144.00M $2.18B $-1.64B $-2.89B $417.00M $263.00M $-1.40B $-1.30B $2.52B $-139.00M $-1.55B $-2.10B $1.05B $-1.45B $-527.00M $-3.67B $1.40B
Other Non Cash Items $2.57B $2.44B $2.75B $1.13B $-47.00M $10.60B $549.00M $1.03B $1.65B $939.00M $851.00M $139.00M $-510.00M $2.41B $-331.00M $4.74B $-228.00M $-325.00M $143.00M $152.00M
Net Cash Provided by Operating Activities $9.29B $5.64B $3.09B $246.00M $7.72B $3.70B $1.34B $4.43B $5.60B $4.30B $4.76B $5.03B $4.80B $2.49B $1.79B $4.01B $2.17B $3.37B $707.00M $4.79B
Investments in Property Plant and Equipment $-783.00M $-791.00M $-861.00M $-989.00M $-902.00M $-965.00M $-1.01B $-1.15B $-1.13B $-1.13B $-984.00M $-1.21B $-1.17B $-934.00M $-1.13B $-1.51B $-1.52B $-668.00M $-986.00M $-1.14B
Acquisitions Net $-598.00M $- $-746.00M $- $902.00M $-10.71B $-1.33B $- $-121.00M $- $- $-11.26B $1.00M $-1.63B $-14.00M $-3.15B $-586.00M $-321.00M $-2.54B $-25.00M
Purchases of Investments $-169.00M $-49.00M $-15.00M $-251.00M $-117.00M $-25.00M $-562.00M $-494.00M $-5.00M $-333.00M $-372.00M $- $1.17B $- $-1.00M $-1.02B $-1.00M $-28.00M $-49.00M $-822.00M
Sales Maturities of Investments $50.00M $60.00M $260.00M $169.00M $704.00M $285.00M $500.00M $12.00M $335.00M $373.00M $1.00M $529.00M $111.00M $- $386.00M $918.00M $2.00M $76.00M $1.82B $1.16B
Other Investing Activities $-2.35B $-289.00M $-14.00M $1.12B $-921.00M $-33.00M $37.00M $-117.00M $-45.00M $12.00M $182.00M $-106.00M $-1.17B $-143.00M $25.00M $-11.00M $-54.00M $59.00M $136.00M $58.00M
Net Cash Used for Investing Activities $-3.85B $-1.07B $-1.38B $53.00M $-334.00M $-11.44B $-2.36B $-1.75B $-962.00M $-1.08B $-1.17B $-12.05B $-1.06B $-2.71B $-738.00M $-4.78B $-2.15B $-882.00M $-1.63B $-763.00M
Debt Repayment $-1.00M $3.60B $-751.00M $-3.00M $-1.95B $-1.75B $-1.00M $-1.00M $-1.00B $- $-1.25B $6.77B $- $- $-365.00M $2.86B $-2.31B $2.83B $1.63B $182.00M
Common Stock Issued $- $- $- $- $- $- $- $265.00M $10.00M $97.00M $12.00M $- $- $- $- $- $- $- $- $-
Common Stock Repurchased $-444.00M $-251.00M $-122.00M $-393.00M $-466.00M $-338.00M $-149.00M $-265.00M $-10.00M $- $- $-18.00M $-583.00M $-239.00M $- $- $- $- $-1.28B $-1.05B
Dividends Paid $-1.95B $-1.99B $-1.95B $-1.85B $-1.85B $-1.89B $-1.85B $-1.75B $-1.75B $-1.77B $-1.75B $-1.64B $-1.65B $-1.67B $-1.65B $-1.54B $-1.54B $-1.58B $-1.55B $-1.41B
Other Financing Activities $-27.00M $-147.00M $9.00M $3.00M $-3.00M $7.73B $-51.00M $197.00M $45.00M $-7.00M $-91.00M $101.00M $-42.00M $3.67B $-88.00M $57.00M $-28.00M $-114.00M $-290.00M $262.00M
Net Cash Used Provided by Financing Activities $-2.42B $1.22B $-2.81B $-2.25B $-4.27B $3.76B $-2.05B $-1.55B $-2.70B $-1.78B $-3.09B $5.21B $-2.27B $1.76B $-2.10B $1.37B $-3.85B $1.14B $-1.49B $-2.01B
Effect of Forex Changes on Cash $294.00M $-82.00M $-138.00M $186.00M $-157.00M $-93.00M $87.00M $366.00M $-412.00M $-309.00M $-55.00M $-68.00M $-46.00M $78.00M $-97.00M $164.00M $87.00M $65.00M $-63.00M $43.00M
Net Change in Cash $3.34B $5.67B $-1.24B $-1.74B $2.94B $-4.03B $-3.04B $1.49B $1.53B $1.14B $447.00M $-1.88B $1.42B $1.61B $-1.14B $764.00M $-3.75B $3.69B $-2.47B $2.06B
Cash at End of Period $14.69B $11.35B $5.67B $6.91B $8.64B $5.70B $9.74B $12.77B $11.28B $9.75B $8.61B $8.17B $10.05B $8.63B $7.02B $8.16B $7.40B $11.15B $7.46B $9.93B
Cash at Beginning of Period $11.35B $5.67B $6.91B $8.64B $5.70B $9.74B $12.77B $11.28B $9.75B $8.61B $8.17B $10.05B $8.63B $7.02B $8.16B $7.40B $11.15B $7.46B $9.93B $7.87B
Operating Cash Flow $9.29B $5.64B $3.09B $246.00M $7.72B $3.70B $1.34B $4.43B $5.60B $4.30B $4.76B $5.03B $4.80B $2.49B $1.79B $4.01B $2.17B $3.37B $707.00M $4.79B
Capital Expenditure $-783.00M $-791.00M $-861.00M $-989.00M $-902.00M $-965.00M $-1.01B $-1.15B $-1.13B $-1.13B $-984.00M $-1.21B $-1.17B $-934.00M $-1.13B $-1.51B $-1.52B $-668.00M $-986.00M $-1.14B
Free Cash Flow $8.51B $4.85B $2.23B $-743.00M $6.82B $2.74B $332.00M $3.28B $4.48B $3.17B $3.78B $3.82B $3.62B $1.56B $657.00M $2.49B $657.00M $2.70B $-279.00M $3.66B


Merck & Stock Forecast

Analyst ratings, price targets, and earnings estimates for MRK.

MRK Analyst Ratings

Strong Buy

Buy
22
Hold
2
Sell
0

Based on 24 analysts in the past 3 months

MRK Stock 12 Month Forecast

$121.33

▲ (37.56% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$121.33 (37.6%)
Lowest Price Target
$ (0.0%)

Based on 3 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $69.54B
Average $65.80B
Low $64.45B
16 analysts
Net Income Estimates
High $24.41B
Average $20.78B
Low $20.03B
16 analysts
EPS Estimates
High $9.58
Average $9.07
Low $7.86
13 analysts
Revenue Estimates
High $75.50B
Average $69.80B
Low $66.55B
17 analysts
Net Income Estimates
High $27.46B
Average $23.97B
Low $23.62B
17 analysts
EPS Estimates
High $10.78
Average $9.86
Low $9.27
14 analysts
Revenue Estimates
High $73.28B
Average $73.06B
Low $72.83B
16 analysts
Net Income Estimates
High $30.04B
Average $26.33B
Low $21.35B
16 analysts
EPS Estimates
High $11.79
Average $10.74
Low $8.38
8 analysts
Revenue Estimates
High $77.56B
Average $73.55B
Low $71.05B
13 analysts
Net Income Estimates
High $28.51B
Average $26.62B
Low $25.45B
13 analysts
EPS Estimates
High $11.19
Average $10.45
Low $9.99
6 analysts
Revenue Estimates
High $75.50B
Average $71.60B
Low $69.17B
14 analysts
Net Income Estimates
High $26.91B
Average $25.13B
Low $24.02B
14 analysts
EPS Estimates
High $10.57
Average $9.87
Low $9.43
5 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Feb 05, 2025 Terence Flynn Morgan Stanley $106.00 $90.74 16.8%
Dec 02, 2024 Courtney Breen Bernstein $110.00 $100.69 9.2%
Nov 15, 2024 Akash Tewari Jefferies $148.00 $98.36 50.5%
Nov 01, 2024 Evan David Seigerman BMO Capital $136.00 $101.88 33.5%
Oct 09, 2024 Trung Huynh UBS $136.00 $108.88 24.9%
Oct 07, 2024 Carter Gould Barclays $140.00 $109.77 27.5%
Aug 15, 2024 Akash Tewari Jefferies $147.00 $113.49 29.5%
Jul 31, 2024 Colin Bristow UBS $142.00 $112.89 25.8%
Jul 31, 2024 Geoff Meacham Bank of America Securities $145.00 $115.21 25.9%
Jun 12, 2024 Mohit Bansal Wells Fargo $140.00 $131.05 6.8%

Merck & Dividends

Explore Merck & 's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

2.62%

Dividend Payout Ratio

2039.73%

Dividend Paid & Capex Coverage Ratio

1.15x



Merck & Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.81 $0.81 March 17, 2025 March 17, 2025 April 07, 2025 January 28, 2025
$0.81 $0.81 December 16, 2024 December 16, 2024 January 08, 2025 November 19, 2024
$0.77 $0.77 September 16, 2024 September 16, 2024 October 07, 2024 July 23, 2024
$0.77 $0.77 June 17, 2024 June 17, 2024 July 08, 2024 May 28, 2024
$0.77 $0.77 March 14, 2024 March 15, 2024 April 05, 2024 January 23, 2024
$0.77 $0.77 December 14, 2023 December 15, 2023 January 08, 2024 November 28, 2023
$0.73 $0.73 September 14, 2023 September 15, 2023 October 06, 2023 July 25, 2023
$0.73 $0.73 June 14, 2023 June 15, 2023 July 10, 2023 May 23, 2023
$0.73 $0.73 March 14, 2023 March 15, 2023 April 10, 2023 January 24, 2023
$0.73 $0.73 December 14, 2022 December 15, 2022 January 09, 2023 November 29, 2022
$0.69 $0.69 September 14, 2022 September 15, 2022 October 07, 2022 July 26, 2022
$0.69 $0.69 June 14, 2022 June 15, 2022 July 08, 2022 May 24, 2022
$0.69 $0.69 March 14, 2022 March 15, 2022 April 07, 2022 January 25, 2022
$0.69 $0.69 December 14, 2021 December 15, 2021 January 07, 2022 November 30, 2021
$0.65 $0.65 September 14, 2021 September 15, 2021 October 07, 2021 July 27, 2021
$0.65 $0.65 June 14, 2021 June 15, 2021 July 07, 2021 May 25, 2021
$0.65 $0.62023 March 12, 2021 March 15, 2021 April 07, 2021 January 26, 2021
$0.65 $0.62023 December 14, 2020 December 15, 2020 January 08, 2021 November 17, 2020
$0.61 $0.58206 September 14, 2020 September 15, 2020 October 07, 2020 July 28, 2020
$0.61 $0.58206 June 12, 2020 June 15, 2020 July 07, 2020 May 26, 2020

Peers: Drug Manufacturers - General

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
ABBV Logo
AbbVie Inc.
ABBV
$341.08B $193.01 $2.75 $56.34 $26.45
PFE Logo
Pfizer Inc.
PFE
$145.73B $25.72 $0.38 $76.67 $1.83
LLY Logo
Eli Lilly and Company
LLY
$835.31B $879.91 $5.83 $100.04 $48.67
BMY Logo
Bristol-Myers Squibb Company
BMY
$114.90B $56.65 $3.88 $13.23 $3.61
AMGN Logo
Amgen Inc.
AMGN
$158.54B $294.95 $7.62 $34.22 $0.00
GILD Logo
Gilead Sciences, Inc.
GILD
$121.31B $97.34 $4.54 $17.85 $4.43
JNJ Logo
Johnson & Johnson
JNJ
$371.04B $154.11 $13.88 $11.30 $5.77
Ownership